Arthur Levin, a director at Avidity Biosciences, Inc. (NASDAQ:RNA), recently executed a significant stock transaction. According to a recent SEC filing, Levin sold 3,323 shares of common stock on November 19, 2024, at a weighted-average price of $42.12 per share, totaling approximately $139,972. The shares were sold in multiple transactions, with prices ranging from $40.72 to $43.35.
This sale was part of a pre-arranged trading plan under Rule 10b5-1, which Levin adopted on May 26, 2023. Following the transaction, Levin retains direct ownership of 14,830 shares of Avidity Biosciences stock. Additionally, Levin exercised stock options to acquire 3,323 shares at a price of $1.24 per share, which were subsequently sold as part of the transaction.
Avidity Biosciences, based in San Diego, is a company focused on pharmaceutical preparations, and Levin's trading activities are closely watched by investors.
In other recent news, Avidity Biosciences has made significant strides in its clinical trials. Goldman Sachs maintained a Buy rating on Avidity Biosciences with a steady price target of $59.00, highlighting the company's commercial execution as it prepares for the upcoming launch of its major depressive disorder (MDD) treatment. The company reported third-quarter 2024 revenues of $175.4 million and adjusted its full-year revenue guidance for fiscal year 2024 to a range of $665-685 million.
The U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on Avidity's drug candidate, del-desiran, allowing the continuation of the Phase 3 HARBOR trial. Avidity also announced the commencement of a biomarker cohort for its Phase 1/2 FORTITUDE trial, evaluating delpacibart braxlosiran in individuals with facioscapulohumeral muscular dystrophy.
Avidity Biosciences has expanded its sales force by 150 representatives to support the bipolar depression opportunity and set a sales target for its treatment, Caplyta, projecting over $5 billion in sales over the next decade. Goldman Sachs anticipates that Avidity will transition to profitability by 2026 at the earliest. These are some of the recent developments in the company's journey.
InvestingPro Insights
Adding context to Arthur Levin's recent stock transaction, Avidity Biosciences (NASDAQ:RNA) presents a mixed financial picture that investors should consider. According to InvestingPro data, the company's market capitalization stands at $5.18 billion, reflecting significant investor interest despite the company not being profitable over the last twelve months.
One of the InvestingPro Tips highlights that RNA holds more cash than debt on its balance sheet, which could provide financial flexibility as the company continues to develop its pharmaceutical preparations. This strong liquidity position is further supported by another tip indicating that liquid assets exceed short-term obligations, potentially mitigating some of the risks associated with the company's current unprofitability.
The stock's performance has been notably volatile, with a substantial 631.16% price total return over the past year. However, this impressive gain is tempered by a recent 16.86% decline in the past week, aligning with the InvestingPro Tip that the stock has taken a big hit over the last week. This volatility underscores the speculative nature of investments in the biotech sector.
It's worth noting that while the company's revenue for the last twelve months was $10.12 million, it faces challenges with profitability. The gross profit margin stands at a concerning -2,477.69%, which correlates with the InvestingPro Tip highlighting weak gross profit margins. Additionally, analysts do not anticipate the company will be profitable this year, suggesting ongoing financial hurdles.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for RNA, providing a deeper understanding of the company's financial health and market position. These insights can be particularly valuable given the complex nature of the biotech industry and Avidity Biosciences' current financial status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.